Neutralization of interleukin-10 or transforming growth factor-β decreases the percentages of CD4+ CD25+ Foxp3+ regulatory T cells in septic mice, thereby leading to an improved survival

Surgery. 2012 Feb;151(2):313-22. doi: 10.1016/j.surg.2011.07.019. Epub 2011 Oct 6.

Abstract

Objectives: To investigate the role of CD4+ CD25+ Foxp3+ regulatory T cells (Tregs) in septic conditions, and to examine the potential of targeting them for the treatment of sepsis.

Background: Sepsis-induced immunosuppression has long been considered a factor in late mortality of patients with sepsis. Although Tregs are central to the maintenance of immunologic homeostasis and tolerance, little is known about Treg-mediated immunosuppression in the late stages of sepsis.

Methods: Peripheral blood mononuclear cells (MNCs) in septic patients and liver or spleen MNCs collected after a cecal ligation and puncture (CLP) model in C57BL/6 mice were examined to evaluate the roles of Tregs and the correlation of transforming growth factor (TGF)-β or interleukin (IL)-10 with their activity. We next examined the effects of neutralization of TGF-β or IL-10 on the percentages of Tregs in CD4+ T cells and the survival rates of septic mice.

Results: The percentages of Tregs in peripheral blood lymphocytes were significantly increased in patients with sepsis, and there was a significantly positive correlation between serum IL-10 levels and the percentage of Tregs. CLP injury increases the percentages of Tregs in the CD4+ T cells in the spleen, and there was a significantly positive correlation between the percentages of Tregs and the serum IL-10 or TGF-β levels. The neutralization of TGF-β or IL-10 decreased the percentages of Tregs in CD4+ T cells, restored the percentages of CD4+ T cells in spleen MNCs, and improved survival rates in septic mice.

Conclusion: We found an increase in the percentages of Tregs in peripheral blood circulating CD4+ T cells from patients with sepsis, and in splenic MNCs from septic mice, and observed that regulation of Tregs by neutralizing IL-10 or TGF-β might represent a novel strategy for treating the immunosuppressive conditions in sepsis.

MeSH terms

  • Animals
  • Antibodies / pharmacology*
  • Case-Control Studies
  • Cecum / injuries
  • Disease Models, Animal
  • Forkhead Transcription Factors / metabolism*
  • Gastrointestinal Neoplasms / surgery
  • Humans
  • Immunosuppression Therapy
  • Interleukin-10 / blood
  • Interleukin-10 / immunology*
  • Interleukin-2 Receptor alpha Subunit / metabolism*
  • Leukocytes, Mononuclear / pathology
  • Ligation / adverse effects
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Postoperative Complications
  • Sepsis / blood
  • Sepsis / mortality*
  • Sepsis / pathology
  • Survival Rate
  • T-Lymphocytes, Regulatory / drug effects*
  • T-Lymphocytes, Regulatory / immunology
  • T-Lymphocytes, Regulatory / pathology*
  • Transforming Growth Factor beta / blood
  • Transforming Growth Factor beta / immunology*

Substances

  • Antibodies
  • Forkhead Transcription Factors
  • Foxp3 protein, mouse
  • Interleukin-2 Receptor alpha Subunit
  • Transforming Growth Factor beta
  • Interleukin-10